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Abstract
Age-related macular degeneration (AMD) is the leading cause of blindness in the elderly in the developed world. Numerous
genetic factors contribute to the development of the multifactorial disease. We performed a case-control study to assess the
risk conferred by known and candidate genetic polymorphisms on the development of AMD. We searched for genetic
interactions and for differences in dry and wet AMD etiology. We enrolled 213 patients with exudative, 67 patients with dry
AMD and 106 age and ethnically matched controls. Altogether 12 polymorphisms in Apolipoprotein E, complement factor
H, complement factor I, complement component 3, blood coagulation factor XIII, HTRA1, LOC387715, Gas6 and MerTK
genes were tested. No association was found between either the exudative or the dry form and the polymorphisms in the
Apolipoprotein E, complement factor I, FXIII and MerTK genes. Gas6 c.834+7G.A polymorphism was found to be
significantly protective irrespective of other genotypes, reducing the odds of wet type AMD by a half (OR = 0.50, 95%CI:
0.26–0.97, p = 0.04). Multiple regression models revealed an interesting genetic interaction in the dry AMD subgroup. In the
absence of C3 risk allele, mutant genotypes of both CFH and HTRA1 behaved as strongly significant risk factors (OR = 7.96,
95%CI: 2.39 = 26.50, p = 0.0007, and OR = 36.02, 95%CI: 3.30–393.02, p = 0.0033, respectively), but reduced to neutrality
otherwise. The risk allele of C3 was observed to carry a significant risk in the simultaneous absence of homozygous CFH and
HTRA1 polymorphisms only, in which case it was associated with a near-five-fold relative increase in the odds of dry type
AMD (OR = 4.93, 95%CI: 1.98–12.25, p = 0.0006). Our results suggest a protective role of Gas6 c.834+7G.A polymorphism in
exudative AMD development. In addition, novel genetic interactions were revealed between CFH, HTRA1 and C3
polymorphisms that might contribute to the pathogenesis of dry AMD.
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Introduction
Age-related macular degeneration (AMD) is the leading cause of
visual impairment in the elderly in developed countries, most
prominently in white populations [1,2]. The prevalence of the
disease increases with age reaching as much as 15% above the age
of 80 [3]. AMD is a multifactorial disease characterized by
progressive degeneration of the central retina leading to visual
deterioration. Early stages of AMD are characterized by retinal
pigment abnormalities and accumulation of small deposits called
drusen under the macular area of the retina. Two advanced forms
of the disease are distinguished: extensive pigment epithelium
atrophy also referred to as geographic atrophy (GA) leading to
irreversible and untreatable visual deterioration or subretinal
neovascular membrane (SRNVM) formation characterized by
intra- or subretinal invasion of new vessels arising from the
choroid. Multiple methods have been developed to determine the
severity of the disease and to estimate the risk of progression from
early to late stages. The neovascular form is referred to as
exudative or wet type, while AMD without any neovascular
component is considered non-exudative or dry type AMD [4].
Although the etiology of the disease is still largely unclear, several
risk factors have been unequivocally linked to AMD, including
advanced age, European origin and smoking. Other factors
including high cholesterol level, sunlight exposure, blue iris,
oxidative damage, hypertension, obesity and inflammation have
also been linked to AMD development, however, with inconsistent
results [5,6]. Cataract surgery has been shown to increase risk
exclusively of dry late AMD, however carriers of two complement
factor H (CFH) risk alleles are prone to develop all types of AMD
[7].
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In recent years a growing number of evidence has supported the
role of genetic risk factors in AMD pathogenesis. The most widely
studied and strongest genetic risk factors map to genes of the
alternative complement pathway and its regulators, and are most
likely responsible for an imbalance in the complement activation.
Additionally, there is a wide range of chromosome regions and
genes with different functions implicated in AMD pathogenesis.
Because in most studies sharp clinical difference between cases and
controls is ascertained by recruiting cases with unequivocally
advanced phenotype, little is known about the genetic background
of intermediate dry AMD. It is still an open question what makes
the difference in the genetic etiology of exudative and non-
exudative AMD [8].
After the initial reports [9,10,11], numerous case-control studies
have provided supportive evidence for a strong association
between AMD and the p.Tyr402His (rs1061170) polymorphism
of the CFH gene in different populations. According to a very
recent meta-analysis of 24 case-control studies the p.Tyr402His
variant confers a 2-fold higher risk of late-AMD per copy in
individuals of European descent [12].
Other components of the complement system have also been
implicated in AMD pathogenesis. The initial report demonstrated
that the p.Arg102Gly (rs2230199) polymorphism in the Comple-
ment factor 3 (C3) gene confers statistically significant risk to AMD
with an odds ratio of 1.7 for heterozygotes and 2.6 for
homozygotes in comparison to wild type subjects [13]. Later
similar odds ratios were reported equally contributing to early and
late AMD. The risk was independent of CFH p.Tyr402His and
LOC387715 p.Ala69Ser polymorphisms [14,15].
The rs10033900 polymorphism of Complement factor I (CFI), a
proteolytic regulatory enzyme inactivating C3b has been shown to
be associated with AMD [16,17], however a recent paper failed to
confirm this association [18].
Strong association has been confirmed between AMD and the
p.Ala69Ser (rs10490924) polymorphism in LOC387715 coding a
protein of unknown function [19,20] or a promoter SNP of the
HTRA serine peptidase 1 (HTRA1) gene (rs11200638)
[21,22,23,24]. These two polymorphisms are located in close
vicinity and it is still a subject of debate which of the two plays a
role in the pathomechanism of the disease.
Although lipids are major components of drusen, proteins
involved in lipid transportation have been linked to AMD
pathogenesis only recently [25]. Apolipoprotein E (ApoE), a
polymorphic gene with three common allelic variants (E2, E3 and
E4) has also been connected to the pathogenesis of AMD. E3 is the
major allele among whites. E4 allele has been reported to decrease
AMD risk, or at least delay the occurrence of the disease. In
contrast, the presence of the E2 allele is associated with increased
risk and younger age at diagnosis [26,27,28]. ApoE E4 proved to
be protective with an odds ratio of 0.5 (95%CI: 0.29–0.86) in a
study comprising of 3137 individuals [29]. Another study
demonstrated a protective effect of the E4 allele only in the
neovascular AMD patient group with an OR of 0.61 (95%CI:
0.38–0.97) [30]. In contrast with these findings, a Spanish study
reported an increased risk for AMD due to the ApoE E4 allele,
with an OR of 5.6 [31]. Previously we could not demonstrate
statistically significant association between ApoE alleles and AMD
in a Hungarian population. However, the potential risk factor E2
allele was less frequent in patients than in controls (0.066 and 0.1,
respectively) while the E4 allele was more frequent in the patient
group than in controls (0.108 versus 0.084, respectively),
interestingly [32]. The somewhat inconsistent findings on the
association of AMD and ApoE called for a recently published
pooled analysis (n = 21.160) demonstrating that the E2 allele in
homozygous form confers risk (OR=1.83, 95%CI: 1.04–3.23) and
the E4 allele is protective (OR=0.72 per haplotype; 95%CI: 0.65–
0.74) in late AMD [33]. A recent well powered case-control study
(including 2187 cases and 2187 age and ethnically matched
controls) demonstrated disease risk of the E2 allele compared to
the E3/E3 genotype (OR=1.32, 95%CI: 1.11–1.58). However,
the E2 allele only conferred risk to early AMD in the never smoker
and previously smoker group, while the E4 allele was protective
against early AMD exclusively in the current smoker population
[34].
The growth arrest–specific gene 6 (Gas6) product is a vitamin K
dependent protein secreted by leukocytes and endothelial cells in
response to injury. Gas6 has a high structural homology with the
natural anticoagulant protein S. It has not been implicated in
AMD pathogenesis so far, however there are certain functions of
the protein that make it a possible candidate for AMD. It has
growth factor-like properties through its interaction with receptor
tyrosine kinases of the TAM family; Tyro3, Axl and MerTK, this
way it contributes to the regulation of angiogenesis, cell survival,
proliferation, migration and adhesion, making it a relevant
participant of biological processes like atherogenesis and throm-
bosis [35,36,37,38]. Recently, we found that Gas6 is present in the
human circulation [39]. A Gas6 polymorphism (c.834+7AA
genotype) was identified as a common SNP in the general
population and gave the strongest association with stroke [40].
Others found similar association with acute coronary syndrome,
and type 2 diabetes [36,40,41]. TAM receptor tyrosine kinases
and their ligands Gas6 and Protein S are essential for the
phagocytosis of apoptotic cells and membranes in the immune,
nervous, and reproductive systems [42]. Moreover, MerTK
receptor is the key player involved in photoreceptor outer segment
phagocytosis by RPE cells. MerTK knock-out mice develop almost
total degeneration of the retinal photoreceptor layer by 10 weeks
of age [43,44,45]. MerTK SNPs were selected because of their
tagging properties after Haploview analysis of the genotypes
downloaded from the HapMap database for CEU population
(Rel20/phase II Jan06, on NCBI B35 assembly, dbSNP b125).
Haplotype (defined as a group of closely linked polymorphic alleles
in a chromosomal region) tagging SNPs were selected according to
the following parameters: MAF.0.05 in Caucasians, r2.0.8
between each pair of tagged and tagging SNPs in pairwise tagging
and haplotypes coverage down to 5% of their frequency in the
HapMap CEU population for each analysed gene. The 4 tagSNPs
selected belong to a haplotype block and were sufficient to cover
the whole gene [46].
The aim of our present case-control study was to refine the
association of the known polymorphisms and AMD subtypes in
the Hungarian population and to explore the interplay of different
polymorphisms. We considered MerTK and its ligand Gas6 as
candidate genes to play a role in AMD pathogenesis and searched
for association between their polymorphisms and the disease.
Patients and Methods
Ethics Statement
The study was approved by the Institutional Ethics Committee
of the University of Debrecen and the procedures strictly adhered
to the tenets of the declaration of Helsinki.
Patients
In total, 386 subjects were enrolled in the case-control study:
213 patients with exudative AMD, 67 patients with dry AMD and
106 unrelated ethnically matched healthy controls were ascer-
tained in Eastern-Hungary at the Department of Ophthalmology,
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University of Debrecen between 2005 and 2011. The control
group consisted of individuals attending to the Outpatient Clinic
because of refractive disorders, or post-cataract follow-up visits. To
maximize the reliability of our study, we deliberately selected
controls to be somewhat older than patients. Written informed
consent was obtained from all participants. Detailed patient
history was recorded with the use of a questionnaire focusing on
known or suspected non-genetic risk factors of AMD such as
cigarette smoking, exposure to blue light, medical history of acute
myocardial infarction, ischemic heart disease and deep venous
thrombosis. Cigarette smoking was determined in packyears.
Smoking of one pack of cigarettes daily for a period of one year
was considered one packyear. Body mass index (BMI) was
calculated on the actual body height and weight values when
ascertained that no considerable change in body weight occurred
in the past 10 years. An average BMI was calculated in patients
with significant loss or increase of body weight based on body
weight values of the previous 10 years period. Color fundus
photographs were taken of patients and controls. Fluorescein
angiography was used to investigate patients with exudative AMD.
Grading of the severity of the disease was based on the clinical age-
related maculopathy staging system (CARMS) [4]. There were
5,3,18,6 and 35 patients in the dry AMD group characterized as
CARMS grade 2b, 2c, 3a, 3b and 4, respectively.
For statistical analysis, patients were classified according to the
more severely affected eye into two groups corresponding to either
dry or wet AMD. No signs of AMD, such as abnormal
pigmentation or drusen were observed in controls. Color fundus
photographs and fluorescein angiograms were evaluated by two
experienced ophthalmologist (T.L. and L.G.). Patients or controls
with other ocular diseases interfering with reliable evaluation of
AMD were not included in the study.
Molecular genetic methods
Molecular genetic methods for the detection of the common
ApoE alleles, CFH p.Tyr402His polymorphism, LOC387715
rs10490924 (p.A69S) and HTRA1 rs11200638 polymorphisms
were used as described earlier [32]. Factor XIII Val34Leu
polymorphism was detected using fluorescent PCR and hybrid-
ization probes [47]. Similar methodology was used for the
genotyping of Gas6 rs8191974 (c.834+7G.A) polymorphism
and for the MerTK rs86016 (g.2920G.A) polymorphism, as
described earlier [46]. Complement C3 rs2230199 (p.Arg102Gly)
polymorphism was tested using a PCR-RFLP method. Amplifica-
tion was performed using the primers: C3R102F: 59- CAG GGA
GTT CAA GTC AGA AAA GG -39 and C3R102R: TCT TGT
CTG TCT GGA TGA AGA GG -39. The 131 bp PCR product
was then subjected to the digestion with CfoI restriction
endonuclease. The sole restriction site of the enzyme in the
PCR product is lost when the mutation is present. The candidate,
most likely a tag SNP, that has been shown to be associated with
AMD, rs10033900 in the complement factor I (CFI) gene was
tested using TaqMan SNP Genotyping assay. TaqMan assays
were also used for the detection of the MerTK I1b rs17835605
(g.4916C.T), MerTK I1c rs10496440 (g.8809A.C) and MerTK
I4 rs7573344 (g.60127A.G), as described earlier [46]. Over 98%
of controls and 96% of patients were genotyped in each test. For
the verification of all in-house mutation detection methods
described above, randomly selected samples were sequenced with
the same primers that were used for PCR amplification. No
discrepancy was found in any of the tested samples.
Statistical methods
Biallelic polymorphisms were tested using the chi-square test for
the deviation of Hardy-Weinberg equilibrium in the control
group. Continuous and categorical variables were described in
terms of mean (SD) and frequency (%), respectively, in AMD
subtype groups and in controls. Unadjusted between-group
comparisons were made using ANOVA or Kruskal–Wallis tests
subject to normality and homoscedasticity assumptions (continu-
ous variables), and Fisher’s exact test (categorical variables).
Unadjusted effects of explanatory variables were estimated using
simple logistic regression and expressed as odds ratios and 95%
confidence intervals (CI). Continuous variables were transformed
with the formula providing the best achievable fit. Categorical
variables were regrouped by pooling groups with close to identical
effects if applicable. Models were fitted for the total sample and for
subsamples formed by restricting cases to dry or wet AMD
variants. Adjusted effects were estimated using multiple logistic
regression. The significance criterion was set at a=0.05 for all
tests, i.e. with no formal adjustment for multiple testing.
Categorical variables were regrouped by pooling groups with
close to identical effects if applicable. Age and cataract surgery
were included as a priori adjustment covariates without effect
interpretations, due to their association with study group inherent
in the control recruitment methods used. Further variable
selection was based on an iterative procedure where models were
started by including all explanatory variables with significant
unadjusted effects, adding each of the rest one by one and keeping
if meaningful, and were made parsimonious by eliminating those
of neutral behavior. Possible interactions between explanatory
variables of models thus developed were systematically evaluated
and kept if found significant. For comparability between dry and
wet AMD variant models, genetic interactions included in any
subtype model were also used in the other. Model fit was checked
using Hosmer–Lemeshow tests for all three final models. As
HTRA1 rs11200638 and LOC rs10490924 are in linkage
disequilibrium, for the analysis HTRA1 rs11200638 was selected.
Results
Characteristics of the study population
In total, 280 patients and 106 controls were enrolled in the
present study. Basic characteristics of the study population are
summarized in Table 1. Patients were divided into two subgroups
according to disease phenotype involving 213 patients in the wet
and 67 patients in the dry AMD subgroups. There was a slight
female predominance among wet AMD patients which is in line
with European data on gender distribution in neovascular AMD
[48].
There was no significant difference between the ages of the dry
and wet subgroups of patients, however, controls were significantly
older than patients as a result of intentionally older control
selection. Cataract surgery was also more common in the control
group because of controls selection methods and probably because
the older age of the controls. There was no statistically significant
difference between patients and controls in terms of frequency of
hypertension, deep venous thrombosis, myocardial infarct, smok-
ing and body mass index. Interestingly, outdoor profession was
significantly more frequent among controls than patients.
Genotype distribution and unadjusted odds ratios of the
analyzed polymorphisms
The genotype distributions in controls and patients are shown in
Table S1. Actual sample number is provided for each test. Small
differences are due to the shortage of DNA sample quantity
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available. The control group showed no statistical difference from
Hardy-Weinberg equilibrium in the case of the tested polymor-
phisms. Minor alleles of genes unequivocally linked to AMD were
more frequent in patients than in controls. Except I1a, MerTK
receptor polymorphisms showed a very low minor allele frequency
and no notable difference between cases and controls. In case of
ApoE the most common E3 allele was slightly more frequent in
patients than in controls while the potential risk factor E2 allele
was less frequent in patients than in controls. The ApoE E4 allele
had similar frequency in all the three groups. Unadjusted odds
ratios, and corresponding p values for each genotype comparison
are shown in Table 2.
Multiple regression models
The model of pooled dry and wet AMD variants revealed
strongly significant adjusted risks in case of the presence of
homozygous polymorphisms in the CFH and HTRA1 genes,
increasing the odds of AMD by more than five and nearly ten
times (OR=5.3, 95%CI: 2.5–11.5, p,0.0001, and OR=9.8,
95%CI: 3.3–29.5, p,0.0001), respectively. No significant inter-
actions were found between any pairs of these variables.
Factors showing significant adjusted associations with dry type
AMD are shown in Table 3. and Figure 1. These are genes C3,
CFH, and HTRA1, with interactions between both C3 and CFH
(p= 0.020) and C3 and HTRA1 (p= 0.024). The heterozygous/
homozygous genotype of C3 carried a significant risk over wild
type genotype in the simultaneous absence of homozygous CFH
and HTRA1 polymorphisms only. In this case it was associated
with a near-five-fold relative increase in the odds of dry type
AMD. The stratum of subjects with homozygous mutated HTRA1
and CFH genes contained an insufficient number and distribution
of observations for C3 effect estimation. In the case of wild type C3
genotype, mutated alleles of both CFH and HTRA1 behaved as
strongly significant risk factors, but reduced to neutrality
otherwise.
Factors found to have remarkable associations with wet type
AMD included the genes Gas6, CFH, and HTRA1 (Table 4,
Figure 1). Gas6 was protective irrespective of other genotypes
(p = 0.04), reducing the odds of wet type AMD by a half. There
was no evidence for the effect of C3 (left in the model for
comparability with the dry variant), and although C3’s odds ratios
specific for different combinations of CFH and HTRA1 genotypes
showed a fairly varied pattern, the interaction was technically not
significant, unlike in the case of the dry AMD. However, there was
some indication that the effect of HTRA1 (homozygous vs. wild
type or heterozygous genotype) was modified by the C3 genotype,
with estimated odds ratios of 45.04 (p= 0.0005) and 4.34 (p= 0.04)
in C3 wild type and hetero/homozygous mutated genotypes,
respectively. Homozygous CFH polymorphism was observed to be
a highly significant risk factor for wet type AMD, with odds ratios
slightly varying around 7.5 depending on whether mutations in C3
were present or not. All models had a sufficient goodness-of-fit by
Hosmer–Lemeshow tests.
Discussion
Our understanding about the genetic causes and therefore
pathological pathways involved in the development of AMD has
increased substantially in the last few years. The p.Tyr402His
polymorphisms of the CFH gene, the rs11200638 polymorphism
of the serine peptidase HTRA1 and the p.Ala69Ser polymorphism
of the LOC387715 gene are unequivocally associated to AMD in
different populations with robust risks. Our results further support
these observations and demonstrate robust and highly significant
adjusted risk conferred by these polymorphisms as shown by the
analysis of the pooled AMD population. After dividing the patient
group to exudative (wet) and non-exudative (dry) subgroups, other
associations and an interesting genetic interplay was revealed. The
rs2230199 polymorphism of the C3 gene contributed significant
disease risk to non-exudative AMD in the simultaneous absence of
homozygous CFH and HTRA1 polymorphisms. Alternative
complement activation is the major biological process linked to
AMD development so far. C3 plays a central role in the alternative
pathway and its role in AMD pathogenesis is supported by
epidemiological and experimental observations. The C3 polymor-
phism had no significant effect on the development of wet AMD in
our study population.
Epidemiological reports on the p.Arg102Gly C3 polymorphism
are usually limited to advanced cases including neovascular AMD
and geographic atrophy. This approach, however, falls short of
detecting any difference between the etiology of dry and wet
AMD. Despite the fact that CFH and C3 are members of the same
biological pathway, no evidence of a genetic interplay between
these two has been demonstrated so far [49]. Carriers of two risk
alleles of the rs2230199 polymorphism of the C3 gene are at
Table 1. Characteristics of the study population.
Attributions Dry AMD Wet AMD Controls p
N=67 N=213 N=106
Female N (%) 34 (50.7) 125 (58.7) 53 (50.0) 0.26
Male N (%) 33 (49.3) 88 (41.3) 53 (50.0) 0.26
Age (year, mean±SD) 75.4 (11.5) 76.0 (7.3) 79.1 (6.1) 0.005
Smoking (packyear, mean± SD) 12.0 (20.1) 11.2 (19.8) 11.4 (21.9) 0.76
BMI (mean±SD) 27.3 (4.5) 27.3 (4.4) 27.6 (4.7) 0.83
Hypertension N (%) 45 (67.2) 159 (75.0) 81 (79.4) 0.21
DVT N (%) 7 (10.4) 15 (7.1) 15 (14.9) 0.09
AMI N (%) 6 (9.0) 19 (9.0) 7 (7.4) 0.90
Outdoor profession N (%) 22 (32.8) 39 (18.5) 38 (38.4) 0.0004
Cataract surgery N (%) 21 (31.3) 48 (22.6) 73 (70.2) ,0.0001
BMI: body mass index, DVT: deep vein thrombosis, AMI: acute myocardial infarction.
doi:10.1371/journal.pone.0050181.t001
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moderate risk to develop AMD compared to wild type subjects
(OR: 1.88, 95%CI: 1.59–2.23) according to a recent meta-analysis
[15]. Besides that, it is well known that, drusen, the hallmark of dry
AMD contains complement factors 3a and 5a among other
inflammatory proteins, which therefore could play a role in drusen
formation and might even have an effect on neovascularisation
[50,51,52,53,54]. Experimental evidence showed that suppression
of the complement cascade in the retina delayed and reversed the
onset of AMD in a monkey model of dry AMD [55]. The effect of
CFH and C3 polymorphisms are mutually exclusive on the risk of
dry AMD in our study population. On the other hand, CFH has a
robust effect on neovascular AMD independent of the C3 status.
Since the two proteins are located in the same biological pathway,
our results can be explained with the stronger effect overriding the
other. Interestingly, the interaction between C3 and HTRA1 is
very similar, which indicates that C3 and HTRA1 are also
competing in dry AMD development. This finding underscores
previous reports on the role of HTRA1 in complement regulation
[56]. Taken together our findings indicate a central role of C3 in
dry AMD formation, however, CFH and HTRA1 genotype have
an influence on the effect of the C3 p.Arg102Gly polymorphism
most likely explained by their complement regulatory activity. CFI
has been associated to AMD development with conflicting results.
Fagerness et al. reported an OR of 0.7 for the lower risk C allele
(p = 6.4661028) of the rs10033900 polymorphism within the CFI
gene in a large population of European descent [16]. Chen et al
found a statistically significant association of the rs2285714 risk
allele and AMD with a moderate OR of 1.31 (95%CI: 1.18–1.45,
p = 3.461027) [57]. Seddon et al. demonstrated that the protective
effect of the hepatic lipase (LIPC) rs10468017 polymorphism on
AMD pathogenesis was stronger in the presence of double wild
type rs10033900 compared to the homozygous polymorphism
[58]. The findings of the original article by Fagerness were
reflected in three case-controls studies. A report on a Japanese
population demonstrated an OR of 0.28 (95%CI: 0.11–0.69,
p = 0.0035) for the rare homozygous CC genotype [59]. The work
of Ennis et al. supports the involvement of the CFI gene in AMD
development by demonstrating four SNP’s in the CFI gene
associating to AMD, however the effect of the rs10033900
polymorphism, which had the strongest association signal in the
original work of Fagerness, was not statistically significant in their
cohort (p = 0.135). Interestingly, the haplotype including
rs10033900 polymorphism and another non-significant polymor-
phism together conferred statistically significant disease risk
(OR=2.15, p= 0.02) [17]. A very well powered case-control
study based on independent samples from England and Scotland
failed to detect any statistically significant effect of the rs10033900
polymorphism on AMD (OR=0.95, 95%CI: 0.83–1.09, p= 0.47)
[18]. Similarly to that, in the present study we could not provide
any additional support for the association of the rs10033900
polymorphism and AMD. Although our sample size is not as large
as some of the cited works, it is large enough to detect strong or
even weak but significant associations with other well established
Table 2. Unadjusted ORs of the examined polymorphisms.
Polymorphism
Genotypes
compared Dry AMD Wet AMD
OR p value OR p value
CFH rs1061170 TC+CC vs. TT 1.30 0.43 3.27 ,0.0001
CFH rs1061170 TC vs. TT 0.86 0.67 2.09 0.0104
CFH rs1061170 CC vs. TC 3.86 0.003 4.17 0.0001
CFH rs1061170 CC vs. TT 3.32 0.01 8.73 ,0.0001
CFH rs1061170 CC vs. TT+TC 3.60 0.002 5.45 ,0.0001
LOC387715
rs10490924
GT+TT vs. GG 1.50 0.20 3.29 ,0.0001
LOC387715
rs10490924
GT vs. GG 1.22 0.56 2.07 0.01
LOC387715
rs10490924
TT vs. GT 3.55 0.03 7.47 ,0.0001
LOC387715
rs10490924
TT vs. GG 4.31 0.01 15.5 ,0.0001
LOC387715
rs10490924
TT vs. GG+GT 3.89 0.01 10.0 ,0.0001
HTRA1 rs11200638 TC+CC vs.TT 1.52 0.19 3.21 ,0.0001
HTRA1 rs11200638 TC vs. CC 1.24 0.52 2.00 0.01
HTRA1 rs11200638 CC vs. TC 4.03 0.03 9.18 ,0.0001
HTRA1 rs11200638 CC vs. TT 5.00 0.01 18.4 ,0.0001
HTRA1 rs11200638 CC vs. TT+TC 4.46 0.01 12.2 ,0.0001
Gas6 rs8191974 AA vs. GA 1.51 0.39 1.00 0.99
Gas6 rs8191974 AA vs. GG 1.03 0.96 0.61 0.21
Gas6 rs8191974 AA vs. GG+GA 1.27 0.60 0.79 0.54
Gas6 rs8191974 GA vs. GG 0.68 0.26 0.61 0.05
Gas6 rs8191974 GA+AA vs. GG 0.75 0.37 0.61 0.04
C3 rs2230199 CG+GG vs. CC 1.55 0.17 1.27 0.3237
C3 rs2230199 CG vs. CC 1.47 0.24 1.22 0.4198
C3 rs2230199 GG vs. CG 1.76 0.48 1.52 0.5409
C3 rs2230199 GG vs. CC 2.59 0.23 1.86 0.3568
C3 rs2230199 GG vs. CC+GC 2.22 0.31 1.73 0.41
CFI rs10033900 CC vs. TC 1.47 0.34 1.21 0.55
CFI rs10033900 CC vs. TT 1.54 0.34 1.31 0.44
CFI rs10033900 TC vs. TT 1.04 0.91 1.09 0.76
FXIII rs5985 GT+TT vs. GG 0.59 0.10 0.66 0.08
FXIII rs5985 GT vs. GG 0.65 0.20 0.64 0.08
FXIII rs5985 TT vs. GT 0.51 0.34 1.15 0.73
FXIII rs5985 TT vs. GG 0.34 0.11 0.74 0.46
FXIII rs5985 TT vs. GG+GT 0.40 0.18 0.90 0.78
Apo-E 3/4+4 vs. 2+2/31.67 0.3897 1.51 0.3512
Apo-E 3/4+4 vs. 3/3 1.00 0.9929 1.02 0.9543
Apo-E 2+2/3 vs. 3/3 0.60 0.2879 0.68 0.2632
Mertk I1a AA vs. GA 0.96 0.9251 1.08 0.8171
Mertk I1a AA vs. GG 0.83 0.7086 1.00 0.9910
Mertk I1a GA vs. GG 0.87 0.6891 0.93 0.7714
Mertk I1b CT vs. CC 0.58 0.1329 0.76 0.2919
Mertk I1b TT vs. CC 2.50 0.0989 1.16 0.7664
Mertk I1b TT vs. CT 4.33 0.0144 1.52 0.4218
Mertk I1c AC vs. AA 0.54 0.2623 1.13 0.7328
Mertk I4 AG vs. AA 0.88 0.7186 0.79 0.3602
Mertk I4 GG vs. AA * * 0.62 0.5352
Table 2. Cont.
Polymorphism
Genotypes
compared Dry AMD Wet AMD
OR p value OR p value
Mertk I4 GG vs. AG * * 0.79 0.7615
*Missing data are due to insufficient minor allele frequency.
doi:10.1371/journal.pone.0050181.t002
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risk factors of AMD as demonstrated by our findings on the CFH,
LOC387715, HTRA1 and C3 polymorphisms. Our results are in
line with studies showing no effect of the rs10033900 polymor-
phism. Although one cannot exclude such an association based on
a single negative result, there are a growing number of
publications falling short of detecting any effect of the polymor-
phism which clearly indicates that the association is not
unequivocal and calls for further epidemiological and functional
analysis to clarify the link between CFI and AMD.
No evidence of association with AMD could be demonstrated in
the case of ApoE alleles. We neither could confirm previous
reports on the protective effect of the E4 allele, nor could we show
any risk related to the E2 allele. Two recent very-well powered
epidemiological studies [33,34] concluded on the disease causing
effect of the E2 allele and the protective role of the E4 allele. Albeit
these convincing studies, our results still do not fit in the line.
Interestingly, we could not observe any statistically significant
disease association with any of the ApoE alleles, moreover the
frequency of the E2 risk allele was higher in controls than in
patients, while the protective E4 allele showed similar frequencies
in the wet AMD and the control group. These data indicate that
ApoE is not a key player in AMD pathogenesis in the Hungarian
population. This can either be explained by a geographical
difference, or by other different environmental factors, probably
the different smoking habits of the Hungarian population.
Candidate gene approach is widely used to identify biological
pathways and genes involved in pathological processes. Based on
their biological functions, we directly tested for disease association
of common polymorphisms in the FXIII, Gas6 and in one of the
Gas6 receptor genes, MerTK. Blood coagulation factor XIII is a
plasma transglutaminase that cross links adjacent fibrin chains in
the final step of the coagulation cascade. In addition, FXIII is
known to participate in wound healing, tissue remodeling and
embryo implantation at least partially through its proangiogenic
effect [60]. The cardioprotective p.Val34Leu polymorphism of the
blood coagulation factor XIII has been associated with accelerated
thrombin activation, recurrent subconjunctival haemorrhage,
intracerebral haemorrhage, and a decreased immune reaction in
humans [61,62,63]. Most importantly, since angiogenesis plays a
crucial role in neovascular AMD, we found it reasonable to
investigate if the polymorphism had any effect on AMD formation.
However, we failed to detect any association of AMD and the
polymorphism in our present study, indicating a neutral polymor-
phism in relation to both dry and wet AMD development.
Gas6, a Protein S structural homologue, has important
functions in the regulation of angiogenesis, cell migration and
proliferation. Its common polymorphism Gas6 c.834+7G.A is
Figure 1. The effect of GAS6 c.834+7G.A polymorphism and genetic interactions on the risk of AMD. Polymorphisms with the
compared genotypes are shown on the left side. Stratum of subjects involved in the corresponding analysis are on the vertical axis. Figures above
markers indicate number of observations for the given stratum Adjusted odds ratios and 95% confidence intervals are represented by dots and lines,
respectively. In the dry AMD group the effect of C3 polymorphism in case of double CFH/HTRA1 homozygousity could not be estimated due to low
observation number. GAS6 was not included as an explanatory variable in the model for dry AMD.
doi:10.1371/journal.pone.0050181.g001
Table 3. Polymorphisms showing significant association with dry AMD using multiple logistic regression.
Polymorphism Genotypes compared Stratum of subjects OR 95% CI p value
C3 rs2230199 CG+GG vs. CC HTRA1: TT+TC CFH: TT+TC 4.93 1.98–12.25 0.0006
CFH rs1061170 CC vs. TT+TC C3: CC 7.96 2.39–26.50 0.0007
HTRA1 rs11200638 TC+CC vs.TT C3: CC 36.02 3.30–393.02 0.0033
Stratum represents genotype of subjects involved in the analysis.
doi:10.1371/journal.pone.0050181.t003
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associated with decreased risk of cardiovascular diseases. Its
receptors (TAM) play a crucial role in phagocytosis of apoptotic
cells in the immune, nervous, and reproductive systems. These
functions make Gas6 and its receptors a potential candidate
involved in both dry and wet AMD development. In the pooled
early and late AMD population the Gas6 polymorphism showed
no statistically significant association to AMD. When analyzing
dry and wet subgroups separately, no association with the dry
AMD could be demonstrated; however a protective effect was
detected in the wet AMD subgroup (p = 0.04). As formation of new
vessels is a hallmark of wet AMD, it is likely that it is this function
of Gas6 that is important in the context of the disease. Gas6 is able
to inhibit VEGF-A signaling through Axl activation of SHP-2
phosphatases [38]. Recently, a similar inhibitory effect has been
shown in metastasis induced angiogenesis [64]. This finding
suggests a role of Gas6 in controlling pathological angiogenesis,
and that c.834+7G.A polymorphism of the GAS6 gene, which
has been linked to disease repeatedly [36,40,41], could have a
direct effect on the function of the gene through an unknown
mechanism. Future epidemiological and functional studies are
required to further evaluate the effect of the GAS6 polymorphism
on AMD development. It is to be noted, that no formal correction
for multiple testing was applied in the multiple logistic regression
analysis, however, this does not invalidate the conclusion that the
suggested effect of the GAS6 polymorphism is worthy of further
investigations.
In our case-control study we confirmed previous findings on the
association of AMD and genetic polymorphisms in the CFH,
LOC387715 and HTRA1 genes, however could not demonstrate
any association with the CFI gene. More interestingly, we found a
genetic interplay of CFH, HTRA1 and C3 genes, showing that the
C3 polymorphism is a major contributor of dry AMD in the
absence of the other polymorphisms, while has no effect on wet
AMD development in our population. This result indicates that
C3 plays a critical role in dry AMD rather than wet AMD
pathogenesis, and its effect can be overdriven by other known
genetic risk factors in the CFH and HTRA1 genes. We detected a
protective effect of a common Gas6 c.834+7G.A polymorphism
on wet AMD formation. Our results suggest a possible new player
and novel genetic interactions in AMD pathogenesis, however our
data should be confirmed in other populations, especially in the
case of the Gas6 polymorphism.
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